Background: Good adherence to highly active antiretroviral therapy (HAART) is required for viral suppression and prevention of drug resistance. Patients’ adherence to HAART has not been determined since the commencement of HAART at the University of Ilorin Teaching Hospital (UITH), Ilorin, Nigeria, over 5 years ago. Objectives: To determine the adherence level of people living with HIV/AIDS (PLWHA) to HAART and identify associated factors. Methodology: A semistructured questionnaire was administered to PLWHA, who were accessing treatment. Sociodemographic, lifestyle, HIV medical, and drug history were obtained from them. Adherence was self-reported. Good adherence was taking of 95% of the prescribed doses of HAART over the preceding 30 days before consultation. Results: Study participants were 253; majority, 58.5%, were females. About 70.8% of them had good adherence. Older age and male sex correlated better with adherence. Conclusion: People living with HIV/AIDS were quite adherent to HAART. Male sex and older age were positive predictors of adherence. Adherence among the young age and females needs strengthening.
UNAIDS/WHO: AIDS epidemic update. 2007. ‘‘UNAIDS/ 07.27E/JC1322E.’’www.data.unaids.org/Pub/EPISlides/2007/2007_epiupdate_en.pdf . Accessed February 24, 2009.
2.
Businessday.Access to ARVs crucial to checking HIV/AIDS scourge. http://www.businessdayonline.com/index.php?option=com_content&view=article&id=8172:access-to-arvs-crucial-to-checking-hivaids-scourge&catid=126:health . Accessed February 24, 2009.
3.
Virtual Hospital.2008National HIV Sero-Prevalence Sentinel Survey among the antenatal clinic attendees. http://www.virtualhospitalng.com/2008ANC%20Survey%20findings.htm . Accessed February 24, 2009.
4.
Friedland G.Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005; 17(1):10-22.
5.
Tadios Y., Davey G.Antiretroviral treatment adherence and its correlates among people living with HIV/AIDS on highly active antiretroviral therapy in Addis Ababa, Ethiopia . EMJ. 2006; 44(3):237-244.
6.
Hogg RS, O’Shaughnessy MV, Gataric N., et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349(9061): 1294.
7.
Remien RVV , Raxach JC, Parker R., Berkman A., Hacker MA, Bastos FIAssessing non-adherence to highly active antiretroviral therapy (HAART) in a context of universal access, in Rio de Janeiro, Brazil. Int Conf AIDS. 2002;14:abstract no. B10445. Available at www.gateway.nlm.nih.gov/MeetingAbstracts/102252798.html. Accessed February 24, 2009.
8.
Rabkin JG, Chesney MATreatment adherence to AIDS medications: the Achilles heel of the new therapeutics . In: Ostrow D, Kalichman S, eds. Psychosocial and Public Health Impacts of New HIV Therapies. Kluwer/Plenum;New York: Kluwer/Plenum ; 1999 :61-68.
9.
Hogg RS, Heath K., Bangsberg D., et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS . 2002;16(7):1051-1058.
10.
Amico K., Rivet J., Harman J., Johnson BTEfficacy of antiretroviral therapy adherence interventions-a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr . 2006;41(3): 285-297.
11.
Sabate E.WHO adherence meeting report. Geneva: World Health Organization; 2001. http://www.who.int/chp/knowledge/publications/adherencerep.pdf . Accessed February 24, 2009.
12.
Carter M.Adherence-Information Series for HIV-Positive People: HIV and Children . 2nd ed. London: NAM ; 2005. http://aids-map.com/en/docs/pdf/hivchildren.pdf . Accessed February 24, 2009.
13.
Paterson DL , Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med . 2000;133(1):21-30.
14.
Shaahu VN, Lawoyin TO, Sangowawa AOAdherence to HAART: the role of health care workers in Makurdi, Nigeria . Afri J Med Med Sci. 2008;37(1):29-36.
15.
Uzochukwu BSC , Onwujekwe OE, Onoka AC, Okoli C., Uguru NP, Chukwuogo OIDeterminants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria . Health Policy Plan. 2009;24(3):189-196.
16.
Alemayehu A. , Kifle W., Sofonias G., Belaineh G., Kebede D.Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia . BMC Public Health . 2008;8:265. http://www.biomedcentral.com/1471-2458-8-265. Accessed February 24, 2009.
17.
Mills EJ, Nachega JB, Buchan I., et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006 ;296(6):679-690.
18.
Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient reported barriers and facilitators. PLoS Med . 2006;3(11):e438. http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030438 . Accessed February 24, 2009.
19.
Bonolo PF, César CC, Acúrcio FA, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005;19(suppl 4):S5-S13.
20.
Molassiotis A., Nahas-Lopez V., Chung WY, Lam SW, Li CK, Lau TFFactors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002; 13(5):301-310.
21.
Mannheimer S., Matts J., Telzak E., et al., for the Terry Beirn Community Programs for Clinical Research on AIDS.Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2004;17(1):10-22.
22.
Wagner G., Miller LGIs the influence of social desirability on patients’ self-reported adherence overrated? J Acquir Immune Defic Syndr. 2004 ;35(2):203-204.
23.
Fischl M., Ribaudo H., Collier A., et al. A randomized trial comparing 24-drug antiretroviral regimens with a 3-drug regimen in advanced HIV disease. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections ; 2002; Seattle, WA. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102263665.html . Accessed February 24, 2009.
24.
Fletcher CV, Testa MA, Haubrich R., et al. Relationships among four measures of medication adherence and virologic response in ACTG 359 (abstract 577). Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections ; 2003; Boston, MA. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102261199.html . Accessed February 24, 2009.
25.
Nieuwkerk PT , Sprangers MA, Burger DM, et al., for the ATHENA project.Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study . Arch Intern Med. 2001;161(16):1962-1968.
26.
Arnsten J., Demas P., Farzadegan H., et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417-1423.
27.
Bangsberg DR , Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population . AIDS. 2000;14(4): 357-366.
28.
Nilsson Schönnesson L., Diamond PM, Ross MW, Williams M., Bratt G.Baseline predictors of three types of antiretroviral therapy (ART) adherence: a 2-year follow-up . AIDS Care. 2006; 18(3):246-253.
29.
Mannheimer SB, Mukherjee R., Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18(7):853-861.
30.
Fedders DODrug use in the elderly: issues of noncompliance. Drug Intell Clin Pharm. 1984;18(2):158-162.
31.
Singh N., Squier C., Hayes P., et al. Determinants of compliance in patients with HIV: prospective assessment with implications for enhancing compliance. Paper presented at: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994; Orlando [abstract I170]. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102213792.html . Accessed February 24, 2009.
32.
Sorensen SJ , Klinge HA, Mravca-Wilkey VL, Elzey J., Fife KHGender-related factors influencing medication and clinic visit adherence in HIV/AIDS patients . Int Conf AIDS. 2002;14: abstract no. WePeB5856. http://gateway.nlm.nih. gov/MeetingAbstracts/ma?f=102254422.html. Accessed February 24, 2009.
